clinical trial · NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 780
Non Small Cell Lung CancerSacituzumab tirumotecanPembrolizumabCisplatinPemetrexedGemcitabineCarboplatinPaclitaxelRescue medication
brief summary
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
started
Apr 3, 2024
primary completion
Feb 21, 2034
completion
Oct 23, 2034
last updated
May 1, 2026
official title
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol